Tolmar
CO - Fort Collins
Biotechnology1 H-1B visas (FY2023)Focus: Small Molecules
Tolmar is a life sciences company focused on Small Molecules.
Oncology
Open Jobs
0
Products & Portfolio (7)
2 discontinued products not shown
ELIGARD KIT
leuprolide acetate
Peak
SUBCUTANEOUS · POWDER
acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy.
advanced prostate cancerprostate cancer
2004
0
ELIGARD KIT
leuprolide acetate
Peak
SUBCUTANEOUS · POWDER
acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy.
advanced prostate cancerprostate cancer
2002
0
ELIGARD KIT
leuprolide acetate
Peak
SUBCUTANEOUS · POWDER
acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy.
advanced prostate cancerprostate cancer
2003
0
ELIGARD KIT
leuprolide acetate
Peak
SUBCUTANEOUS · POWDER
acetate, a gonadotropin releasing hormone (GnRH) agonist, acts as an inhibitor of gonadotropin secretion when given continuously in therapeutic doses. Animal and human studies indicate that after an initial stimulation, chronic administration of leuprolide acetate results in suppression of testicular and ovarian steroidogenesis. This effect is reversible upon discontinuation of drug therapy.
advanced prostate cancerprostate cancer
2002
0
FENSOLVI KIT
leuprolide acetate
Peak
SUBCUTANEOUS · POWDER
acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion (LH and follicle stimulating hormone (FSH)) when given continuously in therapeutic doses. Following an initial stimulation of GnRH receptors, chronic administration of leuprolide acetate results in downregulation of GnRH receptors, reduction in release of LH, FSH and consequent suppression of ovarian and testicular production of estradiol and testosterone respectively. This inhibitory effect is reversible upon discontinuation of drug therapy.
older with central precocious puberty
2020
0
JATENZO
testosterone undecanoate
Peak
ORAL · CAPSULE
androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter syndrome or Leydig cell aplasia, whereas secondary hypogonadism (also known as hypogonadotropic hypogonadism) is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).
2019
0
PALIPERIDONE PALMITATE
paliperidone palmitate
Pre-Launch
INTRAMUSCULAR · SUSPENSION, EXTENDED RELEASE
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2002
Portfolio: 9 approved products
Top TAs: Oncology
H-1B (2023): 1 approval
Portfolio Health
Pre-Launch1 (11%)
Peak6 (67%)
Post-LOE2 (22%)
9 total products
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub